Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome.

@article{Denke2006EzetimibeAT,
  title={Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome.},
  author={Margo A. Denke and Thomas Pearson and Patrick E. McBride and Russell A. Gazzara and William E. Brady and Andrew M. Tershakovec},
  journal={Diabetes & vascular disease research},
  year={2006},
  volume={3 2},
  pages={93-102}
}
This analysis of the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial examined the effectiveness and safety of ezetimibe 10 mg added to ongoing statin therapy in patients with diabetes, metabolic syndrome without diabetes, or neither disorder who had low-density lipoprotein cholesterol (LDL-C) levels exceeding National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) goals. After six weeks of treatment, ezetimibe added to statin reduced LDL-C in patients with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Aberrant de novo cholesterogenesis: Clinical significance and implications.

Clinica chimica acta; international journal of clinical chemistry • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 62 references

update : endorsed by the National Heart , Lung , and Blood Institute

CA Dujovne, MP Ettinger, JF McNeer
Circulation • 2006

Efficacy and safety of ezetimibe co - administered with simvastatin in thiazolidinedione - treated type 2 diabetic patients

RB Goldberg, Teal GJM
Diabetes Obes Metab • 2005

Similar Papers

Loading similar papers…